https://orcid.org/0000-0002-2268-4648
References
- Assistant Secretary for Planning and Evaluation – Office of Health Policy. (2023). —Inflation Reduction Act research series— medicare enrollees’ use and out-of-pocket expenditures for drugs selected for negotiation under the Medicare Drug Price Negotiation Program. U.S. Department of Health and Human Services. Retrieved October 23, 2023, from https://aspe.hhs.gov/sites/default/files/documents/9a34d00483a47aee03703bfc565ffee9/ASPE-IRA-Drug-Negotiation-Fact-Sheet-9-13-2023.pdf
- Cubanski, J. (2023). FAQs about the Inflation Reduction Act’s Medicare drug price negotiation program. Kaiser Family Foundation. Retrieved October 23, 2023, from https://www.kff.org/medicare/issue-brief/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program/
- Dickson, S., & Hernandez, I. (2023). Drugs likely subject to Medicare negotiation, 2026–2028. Journal of Managed Care & Specialty Pharmacy, 29(3), 229–235. Retrieved October 23, 2023, from https://doi.org/10.18553/jmcp.2023.29.3.229
- DiStefano, M. J., Levy, J. F., Odouard, I. C., & Anderson, G. F. (2023). Estimated savings from using added therapeutic benefit and therapeutic reference pricing in United States medicare drug price negotiations. Value in Health, 26(11), 1618–1624. https://doi.org/10.1016/j.jval.2023.08.004
- IQVIA. (2020). Monitoring the impact of COVID-19 on the pharmaceutical market. Retrieved October 31, 2023, from https://www.iqvia.com/-/media/iqvia/pdfs/nordics/covid-reports/nordic_covid-19_cross-country-report-may-2021.pdf
- IQVIA Institute for Human Data Science. (2022). The use of medicines in the U.S. 2022: Usage and spending trends and outlook to 2026. IQVIA. Retrieved October 31, 2023, from https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us-2022/iqvia-institute-the-use-of-medicines-in-the-us-2022.pdf
- Niazi, S. K. (2022). The Inflation Reduction Act: A boon for the generic and biosimilar industry. Journal of Clinical Pharmacy and Therapeutics, 47(11), 1738–1751. https://doi.org/10.1111/jcpt.13783
- Reitsma, M. B., Dusetzina, S. B., Ballreich, J. M., Trujillo, A. J., & Mello, M. M. (2023). Examining opportunities to increase savings from medicare price negotiations. JAMA Internal Medicine, 183(6), 581. https://doi.org/10.1001/jamainternmed.2023.0763
- Rivzi, Z. (2022). Prices for leading insulins will likely not be negotiated under new drug pricing package. Public Citizen. Retrieved October 23, 2023, from https://www.citizen.org/article/prices-for-leading-insulins-will-likely-not-be-negotiated-under-new-drug-pricing-package/
- Rome, B. N., Nagar, S., Egilman, A. C., Wang, J., Feldman, W. B., & Kesselheim, A. S. (2023). Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022. JAMA Health Forum, 4(1), e225218. https://doi.org/10.1001/jamahealthforum.2022.5218
- Seshamani, M. (2023). Medicare drug price negotiation program: Revised guidance, implementation of sections 1191–1198 of the social security Act for initial price applicability year 2026. Department of Health & Human Services. Retrieved October 23, 2023, from https://www.cms.gov/files/document/revised-medicare-drug-price-negotiation-program-guidance-june-2023.pdf
- US Centers for Medicare and Medicaid Services. (2023a). Medicare Part B spending by drug. Retrieved October 23, 2023, from https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-b-spending-by-drug
- US Centers for Medicare and Medicaid Services. (2023b). Medicare Part D spending by drug. Retrieved October 23, 2023, from https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug
- U.S. Department of Health and Human Services. (2023). HHS selects the first drugs for Medicare drug price negotiation. Retrieved October 31, 2023, from https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html
- US Food and Drug Administration. (2023). Search orphan drug designations and approvals. Retrieved October 23, 2023, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/